Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.
Journal: The oncologist
Published: June 01, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.
Journal: Cancer
Published: September 22, 2025
Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.
Journal: The oncologist
Published: July 16, 2025
An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.
Journal: The oncologist
Published: July 15, 2025
Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition.
Journal: Frontiers in oncology
Published: June 26, 2025
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Journal: Therapeutic advances in medical oncology
Published: August 28, 2024
Successful treatment of dermato-neuro syndrome with plasmapheresis.
Journal: BMJ case reports
Published: December 30, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026